The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

The present disclosure provides a reaction method with homogeneous-phase supercritical fluid, including: preparing a supercritical fluid and a solute; supplying the supercritical fluid and the solute into a molecular sieve component to uniformly mix the supercritical fluid and the solute in the molecular sieve component, forming a homogeneous-phase supercritical fluid; and supplying the homogeneous-phase supercritical fluid into a reaction chamber for conducting a reaction. The present disclosure further provides an apparatus for homogeneous-phase supercritical fluid reaction, which can be utilized with the reaction method with homogeneous-phase supercritical fluid

The present disclosure provides a reaction method with homogeneous-phase supercritical fluid, including: preparing a supercritical fluid and a solute; supplying the supercritical fluid and the solute into a molecular sieve component to uniformly mix the supercritical fluid and the solute in the molecular sieve component, forming a homogeneous-phase supercritical fluid; and supplying the homogeneous-phase supercritical fluid into a reaction chamber for conducting a reaction. The present disclosure further provides an apparatus for homogeneous-phase supercritical fluid reaction, which can be utilized with the reaction method with homogeneous-phase supercritical fluid

The present invention provides a method for producing caffeine, wherein the method comprises: (a) combining a coffee extract comprising caffeine with an aqueous organic acid; (b) crystallizing the coffee extract and the aqueous organic acid so as to form caffeine-organic acid co-crystals in an aqueous phase; (c) separating the caffeine-organic acid co-crystals from the aqueous phase; and (d) extracting caffeine from the co-crystals obtained in step (c), wherein step (d) comprises placing the co-crystals in an aqueous solution so as to form a caffeine precipitate and a solution comprising the organic acid. Also provided is a method for producing a decaffeinated coffee extract comprising chlorogenic acids.

Disclosed herein is a method and apparatus for synthesizing co-crystals from the vapor phase without the need for liquid solvent. Also disclosed herein are co-crystals formed from the vapor phase, substrates coated with said co-crystals, pharmaceutical compositions thereof and apparatuses for producing said co-crystals.

Disclosed herein is a method and apparatus for synthesizing co-crystals from the vapor phase without the need for liquid solvent. Also disclosed herein are co-crystals formed from the vapor phase, substrates coated with said co-crystals, pharmaceutical compositions thereof and apparatuses for producing said co-crystals.

A neuroprotective compositions containing caffeine or a caffeine analogue and a long chain fatty acyl tryptamide with an aliphatic chain having 16 to 22 carbons linked to a tryptamine, wherein the composition contains from at least 1.5 mg to 600 mg of caffeine per serving or unit dosage of the composition; from at least 0.5 mg to 300 mg of the long chain fatty acyl tryptamide per serving or unit dosage of the composition; and the ratio of long chain fatty acyl tryptamide to caffeine is from 1:1200 to 200:1. Methods are also disclosed for treating or preventing cognitive and movement deficits of a disease, condition or disorder or neurological deterioration that use the disclosed neuroprotective compositions.

A nonaqueous electrolyte solution is provided comprising a nonaqueous solvent containing acetonitrile at 5 vol % to 95 vol %; a lithium salt; and one or more compounds having a structure satisfying the following conditions 1 to 5: 1. being a condensation polycyclic heterocyclic ring compound, 2. containing a pyrimidine backbone in the condensation polycyclic heterocyclic ring, 3. containing 3 or more nitrogen atoms in the condensation polycyclic heterocyclic ring, 4. containing 5 or more sp2 carbons in the condensation polycyclic heterocyclic ring, and 5. having no hydrogen atoms bonded to the nitrogen atoms in the condensation polycyclic heterocyclic ring.

The present disclosure encompasses solid state forms of Resmetirom, in embodiments crystalline polymorphs of Resmetirom, processes for preparation thereof, and pharmaceutical compositions thereof.

Processes and apparatuses for soluble compound recovery using supercritical fluid (SCF) are disclosed. An example process involves solvent extraction of a soluble compound using a SCF from a solid or liquid substrate including, but not limited to, microalgae, plant matter, and polymers. The apparatus comprises SCF, an extraction vessel, a pressure exchanger, a separate soluble compound, and solid or liquid compound separators.